Excipients Used in Pediatric Oral Dosage Forms: Challenges and Perspectives for Safe Hospital Practice
Abstract
The pharmacological management of pediatric patients remains a major challenge, particularly in low-resource settings. Oral dosage forms, widely used in children, require appropriate excipients; however, some of these excipients may induce adverse effects. The aim of this study was to identify the excipients used in pediatric oral formulations available in community pharmacies in order to guide the development of safer hospital formulations. A descriptive study was conducted in a community pharmacy located in the suburbs of Dakar over a three-month period. Pediatric oral pharmaceutical products were surveyed, and for each product, the international nonproprietary name (INN), dosage form, packaging volume, therapeutic indication, and list of excipients were collected. Data were entered and analyzed using Microsoft Excel 2016. A total of 200 pharmaceutical products corresponding to 96 international nonproprietary names were identified. Solutions were the most frequent dosage forms (46.5%), followed by powders (31.8%) and suspensions (21.7%). The most common packaging volumes ranged from 51 to 100 mL, and antibiotics were the most frequently encountered therapeutic class. The most commonly used excipients were sucrose, sodium benzoate, and citric acid. Sucrose served as the main sweetener to mask the bitter taste of active ingredients, sodium benzoate acted as a preservative, and citric acid was used as a pH regulator. Flavoring agents and preservatives were the most represented categories. The findings highlight the widespread use of sweeteners and preservatives, which are essential for the acceptability and stability of liquid formulations, although several of these excipients may pose potential risks for infants. A better understanding of these substances is therefore necessary to optimize pediatric hospital formulations. The development of locally adapted formulations using safe and available excipients appears essential to improve the safety and efficacy of pediatric treatments in Senegal. Overall, excipients play a crucial role in pediatric drug formulation by influencing stability, preservation, and palatability, and this study underscores the need for increased vigilance regarding excipients with known effects while supporting the development of hospital preparations tailored to local needs.
Keywords: Pediatric oral dosage forms; Excipients; Pharmaceutical formulation; Hospital preparations; Drug safety
Keywords:
Pediatric oral dosage forms, Excipients, Pharmaceutical formulation, Hospital preparations, Drug safetyDOI
https://doi.org/10.22270/jddt.v16i5.7730References
1. Nahata MC, Allen LV. Extemporaneous drug formulations. Clin Ther. 2008;30(11):2112-2119. https://doi.org/10.1016/j.clinthera.2008.11.020 PMid:19108799
2. Fontan JE, Mille F, Brion F. Drug administration in hospitalized children. Arch Pediatr. 2004;11:1173-1184. https://doi.org/10.1016/j.arcped.2004.06.024 PMid:15475272
3. Pourrat M, Delescluse C, Merlin S, Sauvion S, Carret S, Fontan J. Oral drug administration in infants: preliminary risk analysis in a pediatric hospital unit. Ann Pharm Fr. 2014;72(2):112-121. https://doi.org/10.1016/j.pharma.2013.11.002 PMid:24630313
4. De Giorgi I. Safety of drug preparation and administration in pediatrics. Doctoral thesis in pharmaceutical sciences. University of Geneva and Lausanne; 2010.
5. Abdoulaye El Habib BA. Estimation of pediatric compounding needs in selected hospital settings in Senegal. Doctoral thesis in pharmacy, Cheikh Anta Diop University (UCAD); 2016.
6. Autret-Leca E, Bensouda-Grimaldi L, Le Guellec C, Jonville AP. Children and medicines: application to pediatric prescribing. Arch Pediatr. 2006;13(2):181-185. https://doi.org/10.1016/j.arcped.2005.10.023 PMid:16343869
7. Chilot D, Belay DG, Shitu K. Prevalence and associated factors of common childhood illnesses in sub-Saharan Africa from 2010 to 2020: a cross-sectional study. BMJ Open. 2022;12:e065257. https://doi.org/10.1136/bmjopen-2022-065257 PMid:36379651 PMCid:PMC9668010
8. Pifferi G, Restani P. The safety of pharmaceutical excipients. Il Farmaco. 2003;58(8):541-550. https://doi.org/10.1016/S0014-827X(03)00079-X PMid:12875883
9. Kenya LCK, Beatrice NI, Margaret M. Quality and brands of amoxicillin formulations in Nairobi. Biomed Res Int. 2020;2020:1-14. https://doi.org/10.1155/2020/7091278 PMid:32685520 PMCid:PMC7306854
10. Soremekun R, Irene O, Roseline AW. Prevalence of ethanol and other potentially harmful excipients in pediatric oral medicines: survey of community pharmacies in a Nigerian city. BMC Res Notes. 2019;12:460. https://doi.org/10.1186/s13104-019-4486-7 PMid:31349864 PMCid:PMC6660694
11. Pérez HEM, Nevado SB. Oral liquid pharmaceutical forms (II): excipients. Panorama Actual Med. 2016;40(396):842-848.
12. Nahata MC. Safety of “inactive” excipients in pediatric medicines. Arch Dis Child Fetal Neonatal Ed. 2009;94:F392-F393. https://doi.org/10.1136/adc.2009.160192 PMid:19846397
13. Duro D, Rising R, Cedillo M, Lifshitz F. Association between infantile colic and carbohydrate malabsorption from fruit juices. Pediatrics. 2002;109:797-805. https://doi.org/10.1542/peds.109.5.797 PMid:11986439
14. Koletzko B, Baker S, Cleghorn G, et al. Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group. J Pediatr Gastroenterol Nutr. 2005;41:584-599. https://doi.org/10.1097/01.mpg.0000187817.38836.42 PMid:16254515 PMCid:PMC12073586
15. Bobillot M. Excipients with known effects in pediatrics and neonatology: overview of oral formulations in France. Master thesis. University of Montpellier; 2022.
16. N’Guessan GKC, Bony NF, Tuo-Kouassi AN, Obodji MDB. Optimization of an artisanal pineapple juice formulation for room temperature storage. J Afr Technol Pharm Biopharm. 2023;2(1).
17. Lambros M, Tran T, Fei Q, Nicolaou M. Citric acid: a multifunctional pharmaceutical excipient. Pharmaceutics. 2022;14:972. https://doi.org/10.3390/pharmaceutics14050972 PMid:35631557 PMCid:PMC9148065
18. Bobillot M, Delannoy V, Trouillard A. Potentially harmful excipients in oral liquid formulations used in neonatology and pediatrics. Pharmaceutics. 2024;16:119. https://doi.org/10.3390/pharmaceutics16010119 PMid:38258129 PMCid:PMC10820197
19. Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC. Toxic additives in medicines for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009;94:F236-F240. https://doi.org/10.1136/adc.2008.146035 PMid:19158148
20. American Academy of Pediatrics Committee on Drugs. Inactive ingredients in pharmaceutical products: update. Pediatrics. 1997;99(2):268-278. doi:10.1542/peds.99.2.268 https://doi.org/10.1542/peds.99.2.268 PMid:9024461
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Saliou Khouma , Moussa Diop, Mor Fall , Djiby Faye , Souleymane Aidara , Mamadou Soumboundou
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.